CLVT 📈 CLARIVATE - Overview
Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: JE00BJJN4441
CLVT: Analytics, Research, Intellectual Property, Patent, Trademark, Academic, Software
Clarivate Plc operates as an information services provider in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. It operates through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. The company offers Web of Science and InCites, that analyzes and explores the academic research landscape and manages research information; ProQuest One and Ebook Central that provides comprehensive content collections to institutions in a cost-effective manner; and Alma and Polaris, that manages academic resources and services, connect users, and support research publications. It also provides Patent and Trademark Renewals, that supports paralegal and admin tasks throughout the patent and trademark protection and maintenance process; CompuMark and Derwent, that supports critical decisions around patent and trademark protection, risk, and value creation throughout the innovation and brand lifecycle; IPFolio and Foundation IP that creates a structured environment for the protection and management of global patent and trademark assets. In addition, the company offers Cortellis Competitive Intelligence and Cortellis Drug Discovery Intelligence, that supports the development of new drugs and medical devices from discovery to clinical trials; Cortellis Regulatory Intelligence and OFF-X to monitor drug safety issues and adhere to regulatory protocols; Real World Data and Optimize that inform commercial launch strategy and set pricing for optimal reimbursement. It serves corporations, universities, law firms, government agencies, public libraries, and other professional services organizations. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc was founded in 1864 and is headquartered in London, the United Kingdom. Web URL: https://www.clarivate.com
Additional Sources for CLVT Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CLVT Stock Overview
Market Cap in USD | 4,071m |
Sector | Technology |
Industry | Information Technology Services |
GiC Sub-Industry | Research & Consulting Services |
IPO / Inception | 2018-10-29 |
CLVT Stock Ratings
Growth 5y | -90.5% |
Fundamental | -15.1% |
Dividend | - |
Rel. Strength Industry | -308 |
Analysts | 3.6/5 |
Fair Price Momentum | 3.59 USD |
Fair Price DCF | 15.48 USD |
CLVT Dividends
No Dividends PaidCLVT Growth Ratios
Growth Correlation 3m | -76.1% |
Growth Correlation 12m | -74.5% |
Growth Correlation 5y | -89.5% |
CAGR 5y | -21.81% |
CAGR/Mean DD 5y | -0.45 |
Sharpe Ratio 12m | -0.94 |
Alpha | -73.79 |
Beta | 1.05 |
Volatility | 70.79% |
Current Volume | 6607.9k |
Average Volume 20d | 5695k |
What is the price of CLVT stocks?
As of December 21, 2024, the stock is trading at USD 4.98 with a total of 6,607,922 shares traded.
Over the past week, the price has changed by -2.54%, over one month by -2.16%, over three months by -28.24% and over the past year by -44.23%.
As of December 21, 2024, the stock is trading at USD 4.98 with a total of 6,607,922 shares traded.
Over the past week, the price has changed by -2.54%, over one month by -2.16%, over three months by -28.24% and over the past year by -44.23%.
Is CLARIVATE a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, CLARIVATE is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -15.05 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CLVT as of December 2024 is 3.59. This means that CLVT is currently overvalued and has a potential downside of -27.91%.
Neither. Based on ValueRay Fundamental Analyses, CLARIVATE is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -15.05 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CLVT as of December 2024 is 3.59. This means that CLVT is currently overvalued and has a potential downside of -27.91%.
Is CLVT a buy, sell or hold?
CLARIVATE has received a consensus analysts rating of 3.60. Therefor, it is recommend to hold CLVT.
CLARIVATE has received a consensus analysts rating of 3.60. Therefor, it is recommend to hold CLVT.
- Strong Buy: 3
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecast for CLVT stock price target?
According to ValueRays Forecast Model, CLVT CLARIVATE will be worth about 3.9 in December 2025. The stock is currently trading at 4.98. This means that the stock has a potential downside of -22.09%.
According to ValueRays Forecast Model, CLVT CLARIVATE will be worth about 3.9 in December 2025. The stock is currently trading at 4.98. This means that the stock has a potential downside of -22.09%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 6.3 | 25.9% |
Analysts Target Price | 8.5 | 70.7% |
ValueRay Target Price | 3.9 | -22.1% |